Upper-Extremity Arterial Disease, Hand Ischemia, Raynaud/Buerger Interface, and Repetitive Injury

44.1Mechanism before treatment

Upper-extremity arterial disease should be approached as a mechanism-driven problem rather than as a generic “cold hand” or “blue finger” complaint. The European society-level PAD guidance places subclavian and axillary occlusive disease, Raynaud’s phenomenon, vibration injury, and hand ischemia in the same clinical universe, which is useful for trainees because the first task is to sort proximal inflow disease, distal vasospasm, repetitive-trauma arteriopathy, inflammatory distal-vessel disease — the systemic vasculitic forms of which are developed in vasculitis and inflammatory arteriopathies — and traumatic arterial injury before selecting a therapy. ESC 2024

In atherosclerotic upper-extremity PAD, treatment planning should not stop at a revascularization question. Secondary prevention is part of the operation-minded plan: contemporary ACC/AHA PAD guidance supports single antiplatelet therapy as standard pharmacotherapy for patients with atherosclerotic PAD, and rivaroxaban plus aspirin may be considered when ischemic risk is high and bleeding risk is acceptable. In practice, this means the surgeon should document the vascular bed involved, the ischemic consequences, and the patient’s bleeding risk before escalating antithrombotic intensity, an agent-by-agent and bleeding-risk decision developed in 5antithrombotic therapy. ACC/AHA 2024

For subclavian stenosis, trainees should recognize the evidence boundary around device choice. A Cochrane review specifically searched for randomized trials comparing angioplasty with stenting for subclavian artery stenosis and found no completed or ongoing randomized trials, so procedural selection cannot honestly be presented as trial-settled. The practical teaching point is to individualize the plan around lesion anatomy, access, embolic and restenosis concerns, and institutional experience while being transparent that comparative randomized evidence is absent. Angioplasty versus stenting 2022

Contemporary covered-stent cohort data in supra-aortic arch atherosclerotic occlusive disease, including subclavian and brachiocephalic lesions, provide a device-specific effectiveness signal but not a substitute for randomized comparison. For the vascular surgeon, this supports a careful distinction in conference discussion: “there are contemporary cohort outcomes for primary covered-stent implantation” is different from “covered stenting is proven superior.” Mid-term Outcomes Following 2026

When the presentation follows trauma, the diagnostic and therapeutic lane changes again. A recent vascular-specific cohort of traumatic extremity arterial injuries used computed tomography angiography and reported treatment allocation across primary repair, grafting, endovascular intervention, and conservative management, with outcomes stratified by upper versus lower extremity site. The operative lesson is to let the arterial injury pattern and ischemic consequence drive the choice among repair, graft, endovascular therapy, or observation, rather than forcing every upper-extremity arterial abnormality into an atherosclerotic algorithm. Clinical outcome extremity 2026

44.2Raynaud and digital-ulcer lanes

Raynaud management begins before prescribing. Core warming, smoking cessation, avoidance of cold exposure, and minimizing vasoconstrictor medications form the foundation of care before pharmacologic intensification. Raynaud's Phenomenon Vascular 2021 This is not cosmetic counseling; it is the first therapeutic lane, and it should be written as a treatment plan with specific occupational, medication, and smoking-related targets.

Primary Raynaud’s phenomenon has its own epidemiologic and pharmacologic evidence base. A systematic review and meta-analysis pooled 33 observational studies with 33,733 participants to estimate prevalence, incidence, and risk-factor associations, which supports treating primary Raynaud as a common clinical phenotype rather than a rare diagnosis of exclusion. For drug therapy, the dedicated Cochrane review of calcium-channel blockers provides the canonical first-line drug-class evidence base for primary Raynaud’s, while a separate Cochrane review evaluated other vasodilator classes in primary Raynaud across 15 randomized trials and 635 participants after excluding calcium-channel blockers. Vasodilators primary Raynaud's 2021 · Calcium channel blockers 2016 · Prevalence risk factors 2014

The diagnostic and treatment threshold changes when Raynaud is associated with systemic sclerosis and digital ulcers. The 2023 EULAR evidence review supports bosentan for reducing development of new digital ulcers in systemic sclerosis patients with a history of multiple digital ulcers, based on RAPIDS-1 and RAPIDS-2 randomized trials. Systemic pharmacological treatment 2023 In practical terms, bosentan belongs in the recurrent-ulcer prevention discussion for the systemic-sclerosis digital-ulcer lane, not as a routine treatment for every patient with uncomplicated primary Raynaud.

European Raynaud-specific guidance provides the canonical society-level reference point for diagnosis and pharmacologic management, while broader European PAD guidance places Raynaud, hand ischemia, vibration injury, and upper-extremity PAD within a unified vascular framework. The training point is to avoid siloed care: the same patient may need Raynaud phenotyping, occupational-exposure assessment, medication review, and arterial imaging depending on the presentation. ESC 2024 · ESVM guidelines diagnosis 2017

Botulinum toxin A is best framed as an emerging procedural option for refractory Raynaud rather than standard first-line therapy. A 2026 narrative-plus-case-series treatment review specifically addresses the botulinum-toxin Raynaud literature as a distinct modality from calcium-channel blockers and other vasodilators. For surgical trainees, the important habit is to reserve such discussions for refractory disease after basic measures and conventional pharmacologic lanes have been addressed, and to document the limited nature of the evidence base when counseling patients. Vasodilators primary Raynaud's 2021 · Calcium channel blockers 2016 · Use Botulinum Toxin 2026

44.3Buerger disease and repetitive ulnar trauma

Buerger disease should be taught as a tobacco-linked distal ischemic disease in which the most important “procedure” is complete abstinence. Cohort data summarized in the Fazeli review show that continued tobacco use after diagnosis is associated with progressive ischemic events and limb-loss risk on the order of half of continuing-smoker cohorts, whereas complete abstinence is associated with stabilization in most patients. Recent Updates Advances 2021 This makes smoking cessation a limb-preservation intervention, not a lifestyle add-on.

Drug therapy for Buerger disease must be presented with restraint. A Cochrane review found that endothelin-receptor antagonist evidence remains limited to small studies; bosentan showed improvements in digital perfusion and new ulcer development in a single trial, but the effect estimates were too uncertain to justify routine use. Pharmacological treatment Buerger's 2020 Newer CT-perfusion work with intravenous iloprost adds imaging-quantified pharmacodynamic evidence for distal flow response, but this should be understood as mechanistic and protocol-specific evidence rather than broad proof of durable clinical benefit. Effect IV Iloprost 2026

Long-term outcome data in thromboangiitis obliterans provide the prognostic frame for follow-up. A long-term cohort study of Buerger disease complications supplies prognostic-factor and outcome evidence distinct from pharmacotherapy reviews, reminding the surgeon that the endpoint is not merely ulcer healing at one visit but prevention of recurrent ischemic events and limb loss over time. Visceral involvement is also described in a systematic review of thromboangiitis obliterans, so apparently limb-confined disease should still be approached with attention to broader disease-extension possibilities when symptoms point outside the extremity. Visceral bed involvement 2019 · Long-Term Outcome Prognostic 2018

Hypothenar hammer syndrome occupies the repetitive-trauma lane and begins at the bedside. The modified Allen test is highlighted as a screening tool when the history suggests hypothenar trauma; delayed or absent palmar refill after ulnar release points toward ulnar artery and superficial palmar arch occlusion. Hypothenar Hammer Syndrome 2008 A positive or concerning bedside test should not be treated as a complete diagnosis, but it should focus the next imaging step on the ulnar artery and palmar arch.

Imaging for suspected hypothenar hammer syndrome should demonstrate the lesion, not merely “poor flow.” Duplex ultrasonography paired with catheter or CT angiography has been described as confirming the diagnosis by showing segmental ulnar artery occlusion, a classic corkscrew appearance, or focal aneurysmal dilation at the hook of the hamate. BMJ 2019 For acute or subacute occlusive presentations, thrombolysis evidence is limited to small retrospective series and case reports without randomized comparisons, so favorable reperfusion signals must be weighed against selection bias and heterogeneity in lytic agent, dose, and infusion duration. Endovascular Thrombolysis Hypothenar 2021

Hand-arm vibration syndrome belongs beside, not beneath, Raynaud and hypothenar hammer syndrome. A 2017 systematic review and meta-analysis evaluated the association between hand-arm vibration exposure and vascular plus neurologic disease outcomes; newer work adds exposure-response modeling for vibration-induced white finger and pooled individual-participant analysis of host risk factors. Hand-arm vibration risk 2017 Verification may include modality-specific imaging such as Tc-99m hand perfusion scintigraphy, which has been reviewed as a diagnostic approach for occupational vibration-induced vascular injury. IPD 2025 · Exposure-response relation vibration-induced 2026 · Technetium-99m hand perfusion 2022

44.4Clinical integration, follow-up, and evidence boundaries

The practical clinic structure is to assign each patient to a dominant lane, then keep the competing lanes visible. Proximal atherosclerotic disease requires PAD secondary prevention and selective revascularization thinking; Raynaud begins with warming, smoking cessation, cold avoidance, and medication review; Buerger disease turns on tobacco abstinence and longitudinal ischemic surveillance; repetitive-trauma disease requires exposure recognition, bedside testing, and targeted imaging. This integrated approach mirrors society-level guidance that covers upper-extremity PAD, Raynaud, vibration injury, and hand ischemia within one vascular disease framework. ESC 2024 · ACC/AHA 2024 · Recent Updates Advances 2021 · Raynaud's Phenomenon Vascular 2021 When the dominant lane is effort thrombosis or arterial compression at the thoracic outlet, the anatomy and decompression decision belongs with thoracic outlet syndrome; when the presentation is sudden embolic or thrombotic limb threat, the urgency framework belongs with acute limb ischemia.

Follow-up should be designed around the expected failure mode. In Raynaud, failure often means persistent attacks, medication intolerance, or recurrent digital ulcers; in systemic sclerosis with prior multiple digital ulcers, bosentan is supported for reducing new-ulcer development. In Buerger disease, failure is continued tobacco exposure with progressive ischemia and limb-loss risk; in hypothenar hammer syndrome, failure is missed ulnar artery occlusion or aneurysmal disease when the bedside story and Allen test were not pursued with imaging. Systemic pharmacological treatment 2023 · Recent Updates Advances 2021 · BMJ 2019 · Hypothenar Hammer Syndrome 2008

When counseling about interventions, distinguish evidence of feasibility from evidence of superiority. Subclavian angioplasty-versus-stenting randomized evidence is absent in the Cochrane review; covered-stent series provide cohort-level signals; hypothenar hammer thrombolysis literature is limited by small retrospective series and case reports; botulinum toxin for Raynaud remains an emerging, modality-specific literature. Endovascular Thrombolysis Hypothenar 2021 This language is not academic hedging—it protects patients from overpromising and helps trainees choose honest endpoints for consent and follow-up. Angioplasty versus stenting 2022 · Mid-term Outcomes Following 2026 · Use Botulinum Toxin 2026

Occupational and exposure history should be repeated, not asked once. Hand-arm vibration exposure has systematic-review evidence linking it with vascular and neurologic disease outcomes, while newer exposure-response and host-risk analyses emphasize that risk is shaped both by dose and by personal susceptibility. For the surgeon, this means follow-up should include exposure modification, recurrence surveillance, and documentation precise enough for occupational health decisions. IPD 2025 · Hand-arm vibration risk 2017 · Exposure-response relation vibration-induced 2026

A useful final check before discharge from clinic or hospital is to ask whether the diagnosis explains the arterial distribution and whether the treatment matches the mechanism. A digital-ulcer patient with systemic sclerosis is not the same as a young tobacco user with thromboangiitis obliterans, a manual worker with ulnar artery injury at the hook of the hamate, or an older patient with subclavian occlusive disease. Each may present with hand ischemia, but the prevention plan, imaging target, intervention threshold, and follow-up endpoint differ. Systemic pharmacological treatment 2023 · Angioplasty versus stenting 2022 · Recent Updates Advances 2021 · BMJ 2019